Severe recalcitrant cutaneous dermatophyte infections, not responded to topical therapy or oral griseofulvin
2 yrs: 3.3 to 6.6 mg/kg/day PO min. up to 1-2 wksSevere recalcitrant cutaneous dermatophyte infections, not responded to topical therapy or oral griseofulvin
2 yrs: 3.3 to 6.6 mg/kg/day PO min. up to 4 wksRenal Dose Adjustment
Hepatic Dose Adjustment:
See Supplemental Patient Information
Cautions: Use cautiously in
Supplemental Patient Information
Nizoral interacts with :
Pregnancy Category:C
Breastfeeding: Due to limited published experience with ketoconazole during breastfeeding, other agents may be preferred. An exclusively breastfed infant would ingest an average of 0.01 mg/kg/day (0.4% of the maternal weight-adjusted dosage) and a maximum of 0.033 mg/kg/day (1.4% of the maternal weight-adjusted dosage). This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 6 January 2011). This drug is considered safe and compatible with breastfeeding based upon data from AAP Policy Guidelines (available at http://aappolicy.aappublications.org/cgi/content/full/pediatrics;108/3/776 Last accessed 6 January 2011). According to manufacturer data, it is probably excreted in the milk; mothers who are under treatment should not breast feed.
US Trade Name(s)
US Availability
ketoconazole (generic)
Nizoral
Canadian Trade Name(s)
Canadian Availability
ketoconazole (generic)
UK Trade Name(s)
UK Availability
Nizoral
Australian Trade Name(s)
Australian Availability
Nizoral
Antimicrobials
Antifungals (Systemic)Azole Antifungals
Infectious Disease
Antifungals (Systemic)Azole Antifungals
Pricing data from www.DrugStore.com in U.S.A.
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
